Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Phase 2 Completed 72 enrolled Kubota Vision Inc. Otsuka Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.

Timeline

Start: 2009-10
Primary completion: 2012-06
Completion: 2012-10

Publications

Yeong JL, Loveman E, Colquitt JL, Royle P, Waugh N, Lois N. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD013154. doi: 10.1002/14651858.CD013154.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Emixustat	Small molecule	2 mg	Oral
Subject	Emixustat	Small molecule	5 mg	Oral
Subject	Emixustat	Small molecule	7 mg	Oral
Subject	Emixustat	Small molecule	10 mg	Oral

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

Summary

Timeline

Publications

Drugs

Indications